CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine100 enrolled

Overview

This study is a prospective observational clinical trial. Patients who were diagnosed and treated for the first time were enrolled and their surgical pathology was confirmed to be high-grade serous ovarian cancer. At the same time, these patients will receive first-line maintenance treatment with PARP inhibitors after traditional chemotherapy. During the trial period, patients' plasma will be collected before surgery, after chemotherapy, during targeted maintenance therapy, and during disease progression, and ctDNA-specific genomes will be detected, and clinical data will be collected over the same period. It is expected that specific ctDNA can be used to predict the efficacy of PARP inhibitors in patients with ovarian cancer, and to detect the recurrence of the disease early.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

High-grade Serous Ovarian Cancer Circulating Tumor DNA

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Ovarian cancer first diagnosed and treated; 2. Pathologically confirmed as epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer; 3. The stage of the disease is II-IV, and surgery will be performed after evaluation; 4. Age ≥ 18 years old; 5. Subjects and their families fully understand the research plan and sign an informed consent form. Exclusion Criteria: 1. Pathologically confirmed as non-epithelial ovarian cancer; 2. Surgical treatment cannot be performed after evaluation; 3. Malignant tumors found in other parts of the study were found within five years before enrollment or at the time of enrollment; 4. Patients who do not agree to use clinical first-line targeted drugs; 5. Severe mental illness; 6. Severe cardiovascular disease, uncontrollable infection, or other uncontrollable comorbid diseases.

Outcomes

Primary Outcomes

Progression-free survival

To determine the different prognosis of patients after using the PARP inhibitor for first-line maintenance treatment, at the same time, the plasma will be collected and tested for ctDNA before using the PARP inhibitor, during use and when the disease is progressing.

Time frame: about 36 months after using PARP inhibitors

Secondary Outcomes

Overall survival

Time frame: about over 5 years after using PARP inhibitors

Objective response rate

To evaluate the general response of patients with ovarian cancer to PARP inhibitors

Time frame: 36 months after using PARP inhibitors